If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for April 30 2013
DrugPatentWatch Serves Your Competitive Intelligence
Needs
Subscribers have
access to valuable datasets, including:
- Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information
- Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export
- More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
After months of development, BiologicPatentWatch.com is live. Building on the framework of DrugPatentWatch, BiologicPatentWatch provides comprehensive details on FDA approved biologic drugs, developers and patents. The integrated databases allow both freeform searching and dynamic browsing, making it easy to find information on drug patents both in the US and internationally, Orphan Drug Status, trends in […]
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. In an unanimous decision in Bowman v. Monsanto, argued February 19, 2013 and decided May 13, 2013, the U.S. Supreme Court explicitly confirms that the exhaustion doctrine does not […]
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for April 29 2013
DrugPatentWatch Serves Your Competitive Intelligence
Needs
Subscribers have
access to valuable datasets, including:
- Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information
- Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export
- More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
Drug Patent Expirations for May 2013
Tradename
Applicant
Generic Name
Patent Number
Patent Expiration
HUMALOG PEN
Lilly
insulin lispro recombinant
5,514,646
May 7, 2013
GEMZAR
Lilly
gemcitabine hydrochloride
5,464,826*PED
May 7, 2013
HUMALOG MIX 50…
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for April 26 2013
DrugPatentWatch Serves Your Competitive Intelligence
Needs
Subscribers have
access to valuable datasets, including:
- Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information
- Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export
- More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
May 10, 2013
Comments Off on Introducing BiologicPatentWatch: Biotechnology Industry Competitive Intelligence
Posted in: Biotechnology Industry News
BiologicPatentWatch concentrates deep knowledge on biologic drugs from more than 60 biotechnology companies, including more than 2,800 active and expired US patents and 41,000 patents spanning 91 international patent offices.
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
May 7, 2013
Comments Off on Marketspace: Leading biotechnology players, 2002–08: Key products, indications and technologies
Posted in: General Biotechnology
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Go to paper
ABSTRACT: For the full year 2002, the top ten biotechnology houses generated combined revenues (= royalties/licensing income + ethical or product sales; product sales includes both diagnostic and prescription drugs) of US$15.9bn, a 27 per cent increase over 2001. Using Datamonitor’s proprietary forecasting methodology, the ethical sales of the ten leading biotechnology companies (Amgen, Genentech, Serono, Genzyme, Biogen, Chiron, MedImmune, Gilead, IDEC and Celltech) are forecast to grow from US$17…
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
- Management
- Policy
- Finance
- Law
- Regulation
- Bioethics
For more information, see the Journal of Commercial Biotechnology website
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for April 24 2013
DrugPatentWatch Serves Your Competitive Intelligence
Needs
Subscribers have
access to valuable datasets, including:
- Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information
- Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export
- More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for April 16 2013
DrugPatentWatch Serves Your Competitive Intelligence
Needs
Subscribers have
access to valuable datasets, including:
- Patent litigation
- Clinical trial information
- International patent families
- International patent priority and PCT
information
- Patent maintenance
- Full-text patent downloads
- Paragraph IV challenges
- Tentative approvals
- Drug Master Files
- Dynamic search capabilities with data
export
- More…
|
The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
Click here for reuse options!
Copyright 2013 Biotechblog
Like this:
Like Loading...
